University of Washington Overview

Trial Radar AI Insights

University of Washington

The University of Washington (UW) serves as a preeminent global hub for clinical innovation, consistently ranking among the top public research institutions in the world. With a massive phase II–III portfolio and a reputation for pioneering work in protein design and global health, UW provides trial participants access to cutting-edge therapies that often originate within its own laboratories. The institution’s research culture is defined by its "patient-first" approach and its unique ability to translate high-level computational science into clinical applications across the Pacific Northwest and beyond.

• Institution Profile: Seattle, United States · Public · washington.edu
• Therapeutic Strengths: Oncology, Computational Protein Design, Infectious Disease (HIV/Global Health), and Neuroscience
• Research Standing: Ranked #7 globally for Biological Sciences (2025); home to the 2024 Nobel Prize in Chemistry (David Baker) and a 2025 Nobel-recognized alumna (Mary E. Brunkow)
• Partnerships: Flagship alliances include the Bill & Melinda Gates Foundation for global health and the Fred Hutch/UW/Seattle Children’s Cancer Consortium

Clinical Research Infrastructure

The University of Washington clinical research ecosystem spans a vast regional and international network. Its primary domestic operations are anchored by University of Washington Medical Center and Harborview Medical Center, providing specialized care and trial access to the five-state WWAMI region (Washington, Wyoming, Alaska, Montana, and Idaho). This regional reach is supported by the Institute of Translational Health Sciences (ITHS), a Clinical and Translational Science Award (CTSA) hub that streamlines recruitment and multi-site coordination.

For specialized research, the Institute for Protein Design (IPD) stands as a global leader in de novo protein engineering, utilizing proprietary AI tools like RFdiffusion to create novel therapeutic candidates. The university also maintains deep integration with the Fred Hutchinson Cancer Center, ensuring that oncology trials benefit from the combined resources of a National Cancer Institute (NCI)-designated Comprehensive Cancer Center.

Key Specialties and Therapeutic Focus

The university’s research strategy prioritizes high-impact therapeutic modalities, particularly those leveraging artificial intelligence and molecular engineering.

• Computational Protein Design: Led by Nobel Laureate David Baker, the IPD utilizes AI to design proteins from scratch. These "de novo" proteins include enzymes and binders that target diseases with a precision unattainable by native biological molecules. In 2025, the release of RFdiffusion3 further expanded these capabilities to design proteins that interact with DNA and small molecules.
• Precision Immunotherapy: Researchers like Dr. Nora Disis and Dr. Sara Hurvitz lead efforts in developing therapeutic vaccines and bispecific antibodies. The focus remains on recruiting immune cells directly to tumor microenvironments, particularly for advanced breast cancer and HER2-positive malignancies.
• Translational Neuroscience: Through the Alliance for Therapies in Neuroscience (ATN)—a $53 million partnership with Genentech and Roche—UW accelerates drug discovery for Alzheimer’s and Parkinson’s disease.
• Gene and Cell Therapy: Dr. Hans-Peter Kiem, Chair of the American Society of Gene & Cell Therapy, spearheads research into curative gene-editing therapies for blood disorders and HIV.

University of Washington Clinical Trials Landscape

Trial StatisticsApply Below Filters

As of January 2026, the University of Washington manages a robust portfolio of 260 active clinical trials as the lead sponsor, targeting a total enrollment of 747,238 participants across 592 locations. While the average enrollment size is approximately 2,863 participants per trial, several large-scale global health initiatives in Helminthiasis and Filariasis significantly elevate these metrics. The portfolio is heavily focused on interventional research, with a strong emphasis on adult and older adult populations, supported by a diverse array of 156 drug-related and 185 procedure-based interventions. Additionally, the university contributes its expertise to 138 trials as a collaborator.

Key Clinical Trial Updates

Recent developments highlight UW’s shift toward highly specific, AI-driven interventions and global health equity. In 2025, the university celebrated the release of RFdiffusion3, a tool that has already begun influencing the design of next-generation oncology binders. Clinical programs in breast cancer vaccines have moved into expanded phases under the leadership of Dr. Nora Disis, following promising interim safety data.

Looking ahead to 2026, the university is implementing a mandatory Diversity in Clinical Trials policy. This mandate requires all trials to submit comprehensive diversity plans, ensuring that research data reflects the underserved populations of the WWAMI region. Furthermore, the ATN industry-academic alliance is expected to reach primary data readouts for several early-phase CNS assets in late 2026.

Trial Innovation

The University of Washington is a leader in integrating digital health and novel trial designs. The institution frequently utilizes adaptive trial designs that allow for real-time modifications based on interim results, particularly in oncology and infectious disease. The integration of AI extends beyond drug design into Biomedical Informatics, where partnerships with Microsoft and Amazon facilitate cloud-based genomic analysis and the use of large language models to optimize participant screening and real-world evidence (RWE) utilization.

Clinical Trial Participation Guide

To explore active opportunities at the University of Washington, users can leverage the built-in tools on Trial Radar:

• Participation Assistant: Use the Simplify tool to understand complex study protocols, review the What to Expect section for a preview of the trial journey, and use Check Eligibility to see if you meet specific study requirements.
• Contacts & Locations: Navigate to the dedicated tab to find the nearest UW-affiliated site and contact study coordinators directly to discuss enrollment.

Explore University of Washington clinical trials

Discover 50 of 407 clinical trials awaiting your review.